Amgen misses its survival goal in the melanoma phase 3 trial.
Amgen said T-VEC hits its primary endpoint of durable response in patients with metastatic melanoma but missed its second goal of boosting overall survival.
- Forums
- ASX - By Stock
- VLA
- wish i was a medico
wish i was a medico, page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)